Stopped: Pending COVID-19 pandemic; pending product development
This study is designed to evaluate the safety and efficacy of exosome deployment in patients with Craniofacial Neuralgia. Secondarily, this study is designed to rigorously evaluate for any adverse events that may be related to the administration and reception of exosomes.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Brief Pain Inventory (BPI)
Timeframe: 8 weeks from baseline
Patient Health Questionnaire (PHQ-9)
Timeframe: 8 weeks from baseline
Adverse Event Reporting
Timeframe: Baseline to 24 weeks